Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 9:00 PM

Published 10/29/2009 by Medical News Today


Subset Data From Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates Of Hospitalization In Patients With Crohn's Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate - to - severe Crohn's disease during both induction and maintenance treatment.

Share this 

There are no more reports on this story yet.

Related Stories

First Reported 10/23/2009 - Updated 10/24/2009 - 14 Documents (in Health)
Elan shares fall by 20pc as drug-linked disease cases rise
Shares in Elan plunged 20pc to ?3.42 in Dublin yesterday after its multiple sclerosis treatment Tysabri was linked to over 20 cases of a potentially fatal brain disease and the European drug watchdog said it was reviewing its use. Elan finished at ?3.42 ... [Irish Independent - 10/24/2009]
First Reported 10/22/2009 - Updated 10/22/2009 - 1 Documents (in Biology)
Johnson & Johnson - Click to view image in its original context
Johnson & Johnson
Elan focuses on boosting MS drug sales after selling stake to J&J
Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake... ... [FT.com - Health - 10/22/2009]
In Focus
Network

Blogs

sort by: Date | Relevance
Are You or Someone You Know Paying $50,000 a Ye... [Firedoglake - 10/27/2009]
The public option has received the lion’s share of attention in the health care debate, but there is an equally important one relating to generic drugs that could ...
Jane Hamsher: Protecting Pharmaceutical Profits... [The Huffington Post Full Blog Feed - 10/27/2009]
The public option has received the lion's share of attention in the health care debate, but there is an equally important issue relating to generic drugs ...
1

  •  
  •  
  •